David E Griffith Selected Research

Amikacin (A.M.K)

7/2021	Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease.
3/2021	Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease.
1/2021	Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial.
1/2021	Managing Mycobacterium avium Complex Lung Disease With a Little Help From My Friend.
1/2021	Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.
12/2018	Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.
1/2017	Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David E Griffith Research Topics

Disease

26	Lung Diseases (Lung Disease) 07/2021 - 01/2002
8	Infections 03/2021 - 01/2002
8	Tuberculosis (Tuberculoses) 01/2020 - 05/2003
6	Bronchiectasis 01/2019 - 01/2002
4	Cystic Fibrosis (Mucoviscidosis) 12/2017 - 01/2013
3	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2020 - 01/2017
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2019
1	Neoplasms (Cancer) 01/2018
1	Pseudomonas Infections 12/2017
1	Extensively Drug-Resistant Tuberculosis 01/2017
1	Soft Tissue Infections 12/2016
1	Wounds and Injuries (Trauma) 12/2016
1	Surgical Wound Infection 12/2016
1	Wound Infection (Wound Infections) 12/2016
1	Reinfection 08/2014
1	Chronic Obstructive Pulmonary Disease (COPD) 06/2006
1	Toxic Optic Neuropathy 07/2005

Drug/Important Bio-Agent (IBA)

10	MacrolidesIBA 01/2021 - 01/2002
7	Amikacin (A.M.K)FDA LinkGeneric 07/2021 - 01/2017
6	Liposomes (Liposome)IBA 07/2021 - 12/2018
6	Pharmaceutical PreparationsIBA 03/2021 - 10/2006
5	SuspensionsIBA 07/2021 - 12/2018
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 07/2014
3	Rifampin (Rifampicin)FDA LinkGeneric 01/2017 - 11/2003
3	bedaquiline (R207910)IBA 01/2017 - 08/2015
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2002
2	Azithromycin (Zithromax)FDA LinkGeneric 12/2017 - 01/2013
2	Carrier Proteins (Binding Protein)IBA 08/2009 - 10/2005
2	LigandsIBA 08/2009 - 10/2005
2	Clarithromycin (Biaxin)FDA LinkGeneric 10/2006 - 11/2003
2	Ethambutol (Myambutol)FDA LinkGeneric 07/2005 - 11/2003
1	Isonicotinic Acids (Isonicotinic Acid)IBA 01/2020
1	Ethionamide (Trecator-SC)FDA Link 01/2020
1	Linezolid (Zyvox)FDA Link 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019
1	Tobramycin (Nebcin)FDA LinkGeneric 12/2017
1	DiarylquinolinesIBA 01/2017
1	Adenosine Triphosphate (ATP)IBA 01/2017
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2017
1	Isoniazid (Ftivazide)FDA LinkGeneric 01/2017
1	FluoroquinolonesIBA 01/2017
1	TeicoplaninIBA 12/2016
1	Tigecycline (Tygacil)FDA Link 07/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010
1	Interleukin-17 (Interleukin 17)IBA 08/2009
1	CD226 antigenIBA 10/2005
1	MHC class I-related chain AIBA 10/2005
1	Green Fluorescent ProteinsIBA 05/2003

Therapy/Procedure

21	Therapeutics 01/2021 - 01/2002
3	Salvage Therapy 01/2017 - 07/2014
2	Off-Label Use 01/2017 - 08/2015
1	Duration of Therapy 01/2020
1	Drug Therapy (Chemotherapy) 12/2017
1	Injections 01/2017
1	Cesarean Section (Caesarean Section) 12/2016
1	Lasers (Laser) 01/2016